United States Biotechnology & Medical Research

Zymeworks Inc (ZYME)

Track

Track

Zymeworks Inc. experienced recent insider trading activity involving EVP Adam Schayowitz, who sold shares worth approximately $357,557 in October. This follows a period where the stock price appreciated by 22.7% over ninety days. The company previously reported a negative earnings surprise of 10.7% during its August financial disclosure.
Ticker: ZYME Exchange: NYS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Zymeworks Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Schayowitz Adam EVP, Head of R&D Officer
Transaction date
Sale
Price
147.01
Quantity 89,753 -6.8%
Value US$1,158,397
Adam Schayowitz officer Officer
Transaction date
Proposed sale
Price
17.31
Quantity 56,459
Value US$1,125,004
2.5
Jeffrey T L Smith Former Officer Officer
Transaction date
Proposed sale
Price
491.89
Quantity 77,907
Value US$3,409,629
3.8
Leone D Patterson Former officer Officer
Transaction date
Proposed sale
Price
22.60
Quantity 31,641
Value US$715,087
3.8
Leone D Patterson Former officer Officer
Transaction date
Proposed sale
Price
23.17
Quantity 128,548
Value US$2,978,457
0.9
Hollywood Mark EVP & Chief Operating Officer Officer
Transaction date
Sale
Price
22.67
Quantity 6,120 -4.4%
Value US$138,762
3.8
Leone D Patterson Former officer Officer
Transaction date
Proposed sale
Price
23.17
Quantity 6,832
Value US$158,297
2.5
Jeffrey T L Smith Officer Officer
Transaction date
Proposed sale
Price
23.17
Quantity 9,310
Value US$215,713
2.9
Paul Andrew Moore Officer Officer
Transaction date
Proposed sale
Price
23.17
Quantity 9,560
Value US$221,505
0.9
Mark Hollywood Officer Officer
Transaction date
Proposed sale
Price
23.17
Quantity 6,120
Value US$141,800
3.2
Kenneth Galbraith Officer; Director Executive Director
Transaction date
Proposed sale
Price
23.17
Quantity 30,424
Value US$704,924
2.5
Smith Jeffrey T L EVP & Chief Medical Officer Officer
Transaction date
Sale
Price
22.67
Quantity 9,310 -25.8%
Value US$211,090
2.9
Moore Paul Andrew Chief Scientific Officer Officer
Transaction date
Sale
Price
22.67
Quantity 9,560 -16.5%
Value US$216,759
3.2
Galbraith Kenneth Chair & CEO Executive Director
Transaction date
Sale
Price
22.67
Quantity 30,424 -11.8%
Value US$689,819
2.5
Smith Jeffrey T L Officer Officer
Transaction date
Proposed sale
Price
26.62
Quantity 10,538
Value US$280,522
3.2
Kenneth Galbraith Officer; Director Executive Director
Transaction date
Proposed sale
Price
26.62
Quantity 54,343
Value US$1,446,611
2.9
Paul Andrew Moore Officer Officer
Transaction date
Proposed sale
Price
26.62
Quantity 20,110
Value US$535,328
2.5
Smith Jeffrey T L EVP & Chief Medical Officer Officer
Transaction date
Sale
Price
25.10
Quantity 10,538 -36.5%
Value US$264,471
3.2
Galbraith Kenneth Chair & CEO Executive Director
Transaction date
Sale
Price
25.10
Quantity 31,686 -14.1%
Value US$795,220
3.2
Galbraith Kenneth Chair & CEO Executive Director
Transaction date
Sale
Price
25.10
Quantity 22,657 -12.5%
Value US$568,620
2.9
Moore Paul Andrew Chief Scientific Officer Officer
Transaction date
Sale
Price
25.10
Quantity 10,821 -21.1%
Value US$271,574
2.9
Moore Paul Andrew Chief Scientific Officer Officer
Transaction date
Sale
Price
25.10
Quantity 9,289 -22.9%
Value US$233,125
3.2
Galbraith, Kenneth Officer; Director Executive Director
Transaction date
Proposed sale
Price
27.23
Quantity 47,528
Value US$1,294,187
3.2
Galbraith Kenneth Chair & CEO Executive Director
Transaction date
Sale
Price
27.02
Quantity 47,528 -26.3%
Value US$1,284,311
Derek John Michael Miller Former Director Non-Executive Director
Transaction date
Proposed sale
Price
23.82
Quantity 118,000
Value US$2,810,760
3.2
Neil Gallagher Former Director Non-Executive Director
Transaction date
Proposed sale
Price
23.82
Quantity 105,000
Value US$2,501,100
3.1
EcoR1 Capital, LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
11.78
Quantity 5,919 +0.0%
Value US$69,738
3.1
EcoR1 Capital, LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
11.43
Quantity 49,502 +0.3%
Value US$565,847
3.1
EcoR1 Capital, LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
11.52
Quantity 54,760 +0.3%
Value US$630,819
3.1
EcoR1 Capital, LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
11.16
Quantity 73,953 +0.4%
Value US$825,589
3.1
EcoR1 Capital, LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
11.17
Quantity 196,438 +1.1%
Value US$2,193,800
3.1
EcoR1 Capital, LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
11.84
Quantity 120,770 +0.7%
Value US$1,430,170
3.1
EcoR1 Capital, LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
11.85
Quantity 74,360 +0.4%
Value US$881,017
3.1
EcoR1 Capital, LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
11.60
Quantity 48,658 +0.3%
Value US$564,647
3.1
EcoR1 Capital, LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
11.75
Quantity 4,397 +0.0%
Value US$51,658
3.1
EcoR1 Capital, LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
12.24
Quantity 43,848 +0.3%
Value US$536,857
3.1
EcoR1 Capital, LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
12.91
Quantity 53,501 +0.3%
Value US$690,452
3.1
EcoR1 Capital, LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
13.08
Quantity 22,689 +0.1%
Value US$296,847
3.1
EcoR1 Capital, LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
12.78
Quantity 31,033 +0.2%
Value US$396,518
3.1
EcoR1 Capital, LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
12.93
Quantity 73,476 +0.4%
Value US$949,883
3.1
EcoR1 Capital, LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
12.64
Quantity 58,306 +0.3%
Value US$737,233
3.1
EcoR1 Capital, LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
12.65
Quantity 113,880 +0.7%
Value US$1,440,855
3.1
EcoR1 Capital, LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
12.23
Quantity 56,277 +0.3%
Value US$688,465
3.1
EcoR1 Capital, LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
12.48
Quantity 468,356 +2.9%
Value US$5,847,237
3.1
EcoR1 Capital, LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
12.25
Quantity 292,934 +1.8%
Value US$3,587,826
3.1
EcoR1 Capital, LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
11.49
Quantity 320,690 +2.0%
Value US$3,685,851
3.1
EcoR1 Capital, LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
13.87
Quantity 19,748 +0.1%
Value US$273,998
3.1
EcoR1 Capital, LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
13.89
Quantity 121,681 +0.8%
Value US$1,689,541
3.1
EcoR1 Capital, LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
14.01
Quantity 39,029 +0.3%
Value US$546,671
3.1
EcoR1 Capital, LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
13.56
Quantity 54,500 +0.4%
Value US$739,265
3.1
EcoR1 Capital, LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
13.39
Quantity 74,125 +0.5%
Value US$992,875
3.1
EcoR1 Capital, LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
13.13
Quantity 204,098 +1.3%
Value US$2,678,990
3.1
EcoR1 Capital, LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
14.07
Quantity 21,021 +0.1%
Value US$295,829
2.5
Smith Jeffrey T L Officer Officer
Transaction date
Proposed sale
Price
14.46
Quantity 11,110
Value US$160,651
2.9
Moore Paul Andrew Officer Officer
Transaction date
Proposed sale
Price
14.46
Quantity 21,200
Value US$306,552
3.2
Galbraith, Kenneth Officer; Director Executive Director
Transaction date
Proposed sale
Price
14.46
Quantity 57,291
Value US$828,428
2.9
Moore Paul Andrew Chief Scientific Officer Officer
Transaction date
Sale
Price
14.92
Quantity 11,408 -32.8%
Value US$170,254
2.9
Moore Paul Andrew Chief Scientific Officer Officer
Transaction date
Sale
Price
14.92
Quantity 9,792 -39.9%
Value US$146,137
3.2
Galbraith Kenneth Chair & CEO Executive Director
Transaction date
Sale
Price
14.92
Quantity 33,406 -29.2%
Value US$498,554
3.2
Galbraith Kenneth Chair & CEO Executive Director
Transaction date
Sale
Price
14.92
Quantity 23,885 -33.4%
Value US$356,462
2.5
Smith Jeffrey T L EVP & Chief Medical Officer Officer
Transaction date
Sale
Price
14.92
Quantity 11,110 -55.5%
Value US$165,807
3.1
EcoR1 Capital, LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
14.78
Quantity 157,880 +1.1%
Value US$2,333,403
3.1
EcoR1 Capital, LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
14.57
Quantity 146,501 +1.0%
Value US$2,134,446
3.1
EcoR1 Capital, LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
14.47
Quantity 58,988 +0.4%
Value US$853,326
3.1
EcoR1 Capital, LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
14.49
Quantity 101,659 +0.7%
Value US$1,473,181
3.1
EcoR1 Capital, LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
14.38
Quantity 16,692 +0.1%
Value US$240,038
3.1
EcoR1 Capital, LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
14.12
Quantity 11,958 +0.1%
Value US$168,896
2.4
Christopher Astle Former Officer Officer
Transaction date
Proposed sale
Price
8.97
Quantity 86,294
Value US$774,057
2.4
Astle Christopher SVP & Chief Financial Officer Officer
Transaction date
Sale
Price
11.22
Quantity 1,431 -18.0%
Value US$16,050
3.2
Galbraith Kenneth Chair & CEO Executive Director
Transaction date
Sale
Price
11.22
Quantity 5,706 -19.4%
Value US$63,996
2.9
Moore Paul Andrew Chief Scientific Officer Officer
Transaction date
Sale
Price
11.22
Quantity 2,339 -24.1%
Value US$26,233
2.4
Astle Christopher SVP & Chief Financial Officer Officer
Transaction date
Sale
Price
10.65
Quantity 4,563 -36.5%
Value US$48,606
3.2
Galbraith Kenneth Chair & CEO Executive Director
Transaction date
Sale
Price
10.65
Quantity 18,198 -38.2%
Value US$193,849
2.9
Moore Paul Andrew Chief Scientific Officer Officer
Transaction date
Sale
Price
10.65
Quantity 7,460 -43.5%
Value US$79,465
2.4
Astle Christopher Officer Officer
Transaction date
Proposed sale
Price
10.56
Quantity 5,994
Value US$63,297
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-10-09 2026-10-09 S Sale
Schayowitz Adam

EVP, Head of R&D

Officer
89,753 -6.8%
147.01
US$1,158,397 		89,753 -6.8% 147.01 US$1,158,397
2026-10-09 2026-10-09 PrS Proposed sale
Adam Schayowitz

officer

Officer
56,459
17.31
US$1,125,004 		56,459 17.31 US$1,125,004
2026-03-06 2026-03-06 PrS Proposed sale
2.5
Jeffrey T L Smith

Former Officer

Officer
77,907
491.89
US$3,409,629 		77,907 491.89 US$3,409,629
2026-02-17 2026-02-17 PrS Proposed sale
3.8
Leone D Patterson

Former officer

Officer
31,641
22.60
US$715,087 		31,641 22.60 US$715,087
2026-02-13 2026-02-13 PrS Proposed sale
3.8
Leone D Patterson

Former officer

Officer
128,548
23.17
US$2,978,457 		128,548 23.17 US$2,978,457
2026-01-13 2026-01-12 S Sale
0.9
Hollywood Mark

EVP & Chief Operating Officer

Officer
6,120 -4.4%
22.67
US$138,762 		6,120 -4.4% 22.67 US$138,762
2026-01-12 2026-01-12 PrS Proposed sale
3.8
Leone D Patterson

Former officer

Officer
6,832
23.17
US$158,297 		6,832 23.17 US$158,297
2026-01-12 2026-01-12 PrS Proposed sale
2.5
Jeffrey T L Smith

Officer

Officer
9,310
23.17
US$215,713 		9,310 23.17 US$215,713
2026-01-12 2026-01-12 PrS Proposed sale
2.9
Paul Andrew Moore

Officer

Officer
9,560
23.17
US$221,505 		9,560 23.17 US$221,505
2026-01-12 2026-01-12 PrS Proposed sale
0.9
Mark Hollywood

Officer

Officer
6,120
23.17
US$141,800 		6,120 23.17 US$141,800
2026-01-12 2026-01-12 PrS Proposed sale
3.2
Kenneth Galbraith

Officer; Director

Executive Director
30,424
23.17
US$704,924 		30,424 23.17 US$704,924
2026-01-12 2026-01-12 S Sale
2.5
Smith Jeffrey T L

EVP & Chief Medical Officer

Officer
9,310 -25.8%
22.67
US$211,090 		9,310 -25.8% 22.67 US$211,090
2026-01-12 2026-01-12 S Sale
2.9
Moore Paul Andrew

Chief Scientific Officer

Officer
9,560 -16.5%
22.67
US$216,759 		9,560 -16.5% 22.67 US$216,759
2026-01-12 2026-01-12 S Sale
3.2
Galbraith Kenneth

Chair & CEO

Executive Director
30,424 -11.8%
22.67
US$689,819 		30,424 -11.8% 22.67 US$689,819
2026-01-05 2026-01-05 PrS Proposed sale
2.5
Smith Jeffrey T L

Officer

Officer
10,538
26.62
US$280,522 		10,538 26.62 US$280,522
2026-01-05 2026-01-05 PrS Proposed sale
3.2
Kenneth Galbraith

Officer; Director

Executive Director
54,343
26.62
US$1,446,611 		54,343 26.62 US$1,446,611
2026-01-05 2026-01-05 PrS Proposed sale
2.9
Paul Andrew Moore

Officer

Officer
20,110
26.62
US$535,328 		20,110 26.62 US$535,328
2026-01-05 2026-01-05 S Sale
2.5
Smith Jeffrey T L

EVP & Chief Medical Officer

Officer
10,538 -36.5%
25.10
US$264,471 		10,538 -36.5% 25.10 US$264,471
2026-01-05 2026-01-05 S Sale
3.2
Galbraith Kenneth

Chair & CEO

Executive Director
31,686 -14.1%
25.10
US$795,220 		31,686 -14.1% 25.10 US$795,220
2026-01-05 2026-01-05 S Sale
3.2
Galbraith Kenneth

Chair & CEO

Executive Director
22,657 -12.5%
25.10
US$568,620 		22,657 -12.5% 25.10 US$568,620
2026-01-05 2026-01-05 S Sale
2.9
Moore Paul Andrew

Chief Scientific Officer

Officer
10,821 -21.1%
25.10
US$271,574 		10,821 -21.1% 25.10 US$271,574
2026-01-05 2026-01-05 S Sale
2.9
Moore Paul Andrew

Chief Scientific Officer

Officer
9,289 -22.9%
25.10
US$233,125 		9,289 -22.9% 25.10 US$233,125
2025-12-22 2025-12-22 PrS Proposed sale
3.2
Galbraith, Kenneth

Officer; Director

Executive Director
47,528
27.23
US$1,294,187 		47,528 27.23 US$1,294,187
2025-12-22 2025-12-22 S Sale
3.2
Galbraith Kenneth

Chair & CEO

Executive Director
47,528 -26.3%
27.02
US$1,284,311 		47,528 -26.3% 27.02 US$1,284,311
2025-11-24 2025-11-24 PrS Proposed sale
Derek John Michael Miller

Former Director

Non-Executive Director
118,000
23.82
US$2,810,760 		118,000 23.82 US$2,810,760
2025-11-21 2025-11-21 PrS Proposed sale
3.2
Neil Gallagher

Former Director

Non-Executive Director
105,000
23.82
US$2,501,100 		105,000 23.82 US$2,501,100
2025-05-19 2025-05-19 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
5,919 +0.0%
11.78
US$69,738 		5,919 +0.0% 11.78 US$69,738
2025-05-19 2025-05-15 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
49,502 +0.3%
11.43
US$565,847 		49,502 +0.3% 11.43 US$565,847
2025-04-18 2025-04-17 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
54,760 +0.3%
11.52
US$630,819 		54,760 +0.3% 11.52 US$630,819
2025-04-18 2025-04-16 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
73,953 +0.4%
11.16
US$825,589 		73,953 +0.4% 11.16 US$825,589
2025-04-07 2025-04-04 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
196,438 +1.1%
11.17
US$2,193,800 		196,438 +1.1% 11.17 US$2,193,800
2025-04-07 2025-04-03 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
120,770 +0.7%
11.84
US$1,430,170 		120,770 +0.7% 11.84 US$1,430,170
2025-04-02 2025-04-02 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
74,360 +0.4%
11.85
US$881,017 		74,360 +0.4% 11.85 US$881,017
2025-04-02 2025-04-01 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
48,658 +0.3%
11.60
US$564,647 		48,658 +0.3% 11.60 US$564,647
2025-04-02 2025-03-31 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
4,397 +0.0%
11.75
US$51,658 		4,397 +0.0% 11.75 US$51,658
2025-03-27 2025-03-26 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
43,848 +0.3%
12.24
US$536,857 		43,848 +0.3% 12.24 US$536,857
2025-03-27 2025-03-25 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
53,501 +0.3%
12.91
US$690,452 		53,501 +0.3% 12.91 US$690,452
2025-03-24 2025-03-24 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
22,689 +0.1%
13.08
US$296,847 		22,689 +0.1% 13.08 US$296,847
2025-03-24 2025-03-21 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
31,033 +0.2%
12.78
US$396,518 		31,033 +0.2% 12.78 US$396,518
2025-03-24 2025-03-20 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
73,476 +0.4%
12.93
US$949,883 		73,476 +0.4% 12.93 US$949,883
2025-03-19 2025-03-19 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
58,306 +0.3%
12.64
US$737,233 		58,306 +0.3% 12.64 US$737,233
2025-03-19 2025-03-18 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
113,880 +0.7%
12.65
US$1,440,855 		113,880 +0.7% 12.65 US$1,440,855
2025-03-19 2025-03-17 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
56,277 +0.3%
12.23
US$688,465 		56,277 +0.3% 12.23 US$688,465
2025-03-13 2025-03-13 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
468,356 +2.9%
12.48
US$5,847,237 		468,356 +2.9% 12.48 US$5,847,237
2025-03-13 2025-03-12 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
292,934 +1.8%
12.25
US$3,587,826 		292,934 +1.8% 12.25 US$3,587,826
2025-03-13 2025-03-11 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
320,690 +2.0%
11.49
US$3,685,851 		320,690 +2.0% 11.49 US$3,685,851
2025-01-21 2025-01-17 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
19,748 +0.1%
13.87
US$273,998 		19,748 +0.1% 13.87 US$273,998
2025-01-21 2025-01-16 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
121,681 +0.8%
13.89
US$1,689,541 		121,681 +0.8% 13.89 US$1,689,541
2025-01-15 2025-01-15 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
39,029 +0.3%
14.01
US$546,671 		39,029 +0.3% 14.01 US$546,671
2025-01-15 2025-01-14 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
54,500 +0.4%
13.56
US$739,265 		54,500 +0.4% 13.56 US$739,265
2025-01-15 2025-01-13 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
74,125 +0.5%
13.39
US$992,875 		74,125 +0.5% 13.39 US$992,875
2025-01-10 2025-01-10 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
204,098 +1.3%
13.13
US$2,678,990 		204,098 +1.3% 13.13 US$2,678,990
2025-01-10 2025-01-08 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
21,021 +0.1%
14.07
US$295,829 		21,021 +0.1% 14.07 US$295,829
2025-01-06 2025-01-06 PrS Proposed sale
2.5
Smith Jeffrey T L

Officer

Officer
11,110
14.46
US$160,651 		11,110 14.46 US$160,651
2025-01-06 2025-01-06 PrS Proposed sale
2.9
Moore Paul Andrew

Officer

Officer
21,200
14.46
US$306,552 		21,200 14.46 US$306,552
2025-01-06 2025-01-06 PrS Proposed sale
3.2
Galbraith, Kenneth

Officer; Director

Executive Director
57,291
14.46
US$828,428 		57,291 14.46 US$828,428
2025-01-06 2025-01-06 S Sale
2.9
Moore Paul Andrew

Chief Scientific Officer

Officer
11,408 -32.8%
14.92
US$170,254 		11,408 -32.8% 14.92 US$170,254
2025-01-06 2025-01-06 S Sale
2.9
Moore Paul Andrew

Chief Scientific Officer

Officer
9,792 -39.9%
14.92
US$146,137 		9,792 -39.9% 14.92 US$146,137
2025-01-06 2025-01-06 S Sale
3.2
Galbraith Kenneth

Chair & CEO

Executive Director
33,406 -29.2%
14.92
US$498,554 		33,406 -29.2% 14.92 US$498,554
2025-01-06 2025-01-06 S Sale
3.2
Galbraith Kenneth

Chair & CEO

Executive Director
23,885 -33.4%
14.92
US$356,462 		23,885 -33.4% 14.92 US$356,462
2025-01-06 2025-01-06 S Sale
2.5
Smith Jeffrey T L

EVP & Chief Medical Officer

Officer
11,110 -55.5%
14.92
US$165,807 		11,110 -55.5% 14.92 US$165,807
2025-01-02 2025-01-02 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
157,880 +1.1%
14.78
US$2,333,403 		157,880 +1.1% 14.78 US$2,333,403
2025-01-02 2024-12-31 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
146,501 +1.0%
14.57
US$2,134,446 		146,501 +1.0% 14.57 US$2,134,446
2025-01-02 2024-12-30 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
58,988 +0.4%
14.47
US$853,326 		58,988 +0.4% 14.47 US$853,326
2024-12-27 2024-12-27 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
101,659 +0.7%
14.49
US$1,473,181 		101,659 +0.7% 14.49 US$1,473,181
2024-12-27 2024-12-26 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
16,692 +0.1%
14.38
US$240,038 		16,692 +0.1% 14.38 US$240,038
2024-12-27 2024-12-24 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
11,958 +0.1%
14.12
US$168,896 		11,958 +0.1% 14.12 US$168,896
2024-06-11 2024-06-11 PrS Proposed sale
2.4
Christopher Astle

Former Officer

Officer
86,294
8.97
US$774,057 		86,294 8.97 US$774,057
2024-01-08 2024-01-08 S Sale
2.4
Astle Christopher

SVP & Chief Financial Officer

Officer
1,431 -18.0%
11.22
US$16,050 		1,431 -18.0% 11.22 US$16,050
2024-01-08 2024-01-08 S Sale
3.2
Galbraith Kenneth

Chair & CEO

Executive Director
5,706 -19.4%
11.22
US$63,996 		5,706 -19.4% 11.22 US$63,996
2024-01-08 2024-01-08 S Sale
2.9
Moore Paul Andrew

Chief Scientific Officer

Officer
2,339 -24.1%
11.22
US$26,233 		2,339 -24.1% 11.22 US$26,233
2024-01-08 2024-01-05 S Sale
2.4
Astle Christopher

SVP & Chief Financial Officer

Officer
4,563 -36.5%
10.65
US$48,606 		4,563 -36.5% 10.65 US$48,606
2024-01-08 2024-01-05 S Sale
3.2
Galbraith Kenneth

Chair & CEO

Executive Director
18,198 -38.2%
10.65
US$193,849 		18,198 -38.2% 10.65 US$193,849
2024-01-08 2024-01-05 S Sale
2.9
Moore Paul Andrew

Chief Scientific Officer

Officer
7,460 -43.5%
10.65
US$79,465 		7,460 -43.5% 10.65 US$79,465
2024-01-05 2024-01-05 PrS Proposed sale
2.4
Astle Christopher

Officer

Officer
5,994
10.56
US$63,297 		5,994 10.56 US$63,297
Explore more

More insider trading research around Zymeworks Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America